LYMPHOMA, T-CELL
Clinical trials for LYMPHOMA, T-CELL explained in plain language.
Never miss a new study
Get alerted when new LYMPHOMA, T-CELL trials appear
Sign up with your email to follow new studies for LYMPHOMA, T-CELL, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for rare blood cancer: targeted drug soquelitinib faces standard care in phase 3 trial
Disease control Recruiting nowThis study tests a new drug called soquelitinib against standard treatments for people with certain types of T-cell lymphoma that have come back or not responded to therapy. About 150 adults will be randomly assigned to receive either soquelitinib or a standard single-agent chemo…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE3 • Sponsor: Corvus Pharmaceuticals, Inc. • Aim: Disease control
Last updated May 17, 2026 06:22 UTC
-
New hope for Tough-to-Treat T-Cell lymphoma: experimental therapy MB-105 enters phase 2
Disease control Recruiting nowThis study tests an experimental drug called MB-105 in about 46 adults with a type of blood cancer called T-cell lymphoma that has returned or not responded to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is. Participants must have a speci…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: March Biosciences Inc • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New hope for tough lymphomas: first human trial of STP938 begins
Disease control Recruiting nowThis study tests a new drug called STP938 in adults with B-cell or T-cell lymphoma that has returned or not responded to at least two prior treatments. The goal is to find a safe dose and see if the drug can shrink tumors. About 180 participants will receive STP938 alone, with th…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE1, PHASE2 • Sponsor: Step Pharma, SAS • Aim: Disease control
Last updated May 04, 2026 16:22 UTC
-
New hope for rare blood cancers: targeted drug shows promise
Disease control Recruiting nowThis study tests a drug called golidocitnib in people with slow-growing but hard-to-treat T/NK-cell lymphomas that have come back or not responded to prior therapy. About 48 adults will receive the drug to see if it can shrink tumors and control the disease. The goal is to improv…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated May 04, 2026 16:19 UTC
-
New hope: drug may stop lymphoma relapse after transplant
Disease control Recruiting nowThis study tests whether the drug ruxolitinib, taken as a maintenance therapy after a stem cell transplant, can help prevent T-cell lymphoma from coming back and reduce the risk of graft-versus-host disease (GVHD), a common complication where donor cells attack the patient's body…
Matched conditions: LYMPHOMA, T-CELL
Phase: PHASE2 • Sponsor: Jonathan Brammer • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC